Prurigo nodularis, Skin disease/disorder
CLDXCelldex Therapeutics, Inc.Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for Barzolvolimab (CDX-0159) (KIT receptor) in Prurigo nodularis, Skin disease/disorder. The expected timing is based on the latest available company guidance and may change.
5/15/24- First patient dosed in Ph2 trial. 8/7/25- Enrollment ongoing. 11/10/25:- Enrollment continues; initial Ph2 PN data expected H2 2026. 02/25/26:- Ph2 PN enrollment completed; topline data to be presented Summer 2026. 05/07/26:- Phase 2 PN study enrollment complete; topline efficacy and safety data still expected Summer 2026. 07/21/26:- Phase 2 PN study failed efficacy; program discontinued after topline results.
Verification
Confirm timing and program details against the company announcement or filing.